Insmed sells lung-disease treatments with a big new launch (brensocatib).
Insmed Incorporated (INSM) is expected to report earnings on Thursday, October 29, 2026, after the close. Estimated release time 07:00 ET. Consensus EPS estimate is $-0.37.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-05-07 | FY2026 Q1 | $-0.96 | $-0.76 | +21.1% | $305.96M |
| 2026-02-19 | FY2025 Q4 | $-1.07 | $-1.54 | -43.9% | $263.84M |
| 2025-10-30 | FY2025 Q3 | $-1.33 | $-1.75 | -31.6% | $142.34M |
| 2025-08-07 | FY2025 Q2 | $-1.30 | $-1.70 | -30.8% | $107.42M |
| 2025-05-08 | FY2025 Q1 | $-1.34 | $-1.42 | -6.0% | $92.82M |
| 2025-02-20 | FY2024 Q4 | $-1.17 | $-1.32 | -12.8% | $104.44M |
| 2024-10-31 | FY2024 Q3 | $-1.20 | $-1.27 | -5.8% | $93.42M |
| 2024-08-08 | FY2024 Q2 | $-1.24 | $-1.94 | -56.5% | $90.34M |
INSM has beaten consensus EPS in 1 of its last 8 reported quarters.
See INSM on the live calendar →